NantHealth Launches Eviti Connect For Autoimmune Diseases
May 05 2021 - 9:00AM
Business Wire
Proven in oncology, the Eviti Connect payer
solution expands to help reduce reimbursement inefficiencies and
manage drug costs for disease that affects over 50 million people
in the United States
NantHealth, Inc. (NASDAQ: NH), a provider of enterprise
solutions that help businesses transform complex data into
actionable insights, today announced the launch of Eviti Connect
for autoimmune diseases, aimed at helping payers and providers
realize the quickest path to approving cost-effective, quality care
for patients. Eviti Connect is a go-to resource in the oncology
space and has helped providers find evidence-based care for more
than 345,000 cancer patients while saving payers hundreds of
millions of dollars. NantHealth is now expanding the use of its
expertise, data, and resources to aid providers and payers in
navigating the costs and treatment options of autoimmune
diseases.
Approximately 50 million* people in the United States are
currently living with an autoimmune disease, and the associated
direct healthcare cost for treating autoimmune diseases in the
United States is high at around $100 billion** annually. With more
than 80** known autoimmune diseases, it is the second* leading
cause of chronic illnesses, particularly in women.
“We’ve been a customer of the Eviti Connect oncology product for
many years and are now excited to be part of shaping the offering
for autoimmune diseases,” said Mary Barone-Leitch, Vice President
of Medical and Quality Management, Maryland Physicians Care, A
Maryland Managed Care Plan. “Managing the cost of drugs used to
treat autoimmune diseases is a challenge we face, and with the help
of Eviti Connect, we expect to get a better handle on those costs
in a similar fashion we have seen with oncology.”
This next chapter of Eviti, built on a new, flexible, extensible
platform, enables NantHealth to expand into other disease areas
beyond oncology and autoimmune in the future. It helps payers:
- Extend the knowledge of their clinical teams with independent
expertise.
- Streamline staff authorization workflows, allowing them to
focus on more high-value tasks.
- Manage brand, biosimilar, and generic drug use for
best-expected outcomes, pricing, and reimbursement.
- Confirm that member care complies with medical policy, pharmacy
policy, and step therapy requirements.
- Redirect treatment delivery to optimal sites of care when
clinically appropriate to manage costs.
“Patients, providers, and payers deserve comprehensive,
evidence-based guidance for treatment of complex diseases.
Continued improvements in healthcare require more interoperability
and data liberation. So use of the right technology helps all
stakeholders, allowing providers and payers to perform at their
highest levels, while patients have access to the best treatment
and better outcomes,” said Dr. William Flood, Chief Medical Officer
for Eviti at NantHealth. “Eviti Connect is a powerful and proven
tool that gives payers and providers the confidence to prescribe
and reimburse high-quality, value-based care, realizing the
quickest path to approving cost-effective, quality care for
patients. We are thrilled to open up this crucial resource to
autoimmune patients across the country.”
Eviti Connect is a software-as-a-service (SaaS), evidence-based
decision support and treatment validation platform that gives
providers and payers confidence to prescribe and reimburse
high-quality, high-value care. For ten years, it has helped payers
and providers navigate the complexities of cancer care. The launch
of Eviti Connect for autoimmune diseases targets another
increasingly complex healthcare challenge aiming to save time on
appeals and expedite optimal patient care while managing payer
costs.
For more information about Eviti Connect, visit the website at
https://nanthealth.com/products/eviti/
* American Autoimmune Related Diseases Association **National
Institute of Allergy and Infections Diseases
About NantHealth, Inc.
NantHealth, a member of the NantWorks ecosystem of companies,
provides enterprise solutions that help businesses transform
complex data into actionable insights. By offering efficient ways
to move, interpret, and visualize complex and highly sensitive
information, NantHealth enables customers in healthcare, life
sciences, logistics, telecommunications and other industries to
automate, understand and act on data while keeping it secure and
scalable. NantHealth’s product portfolio comprises the latest
technology in payer/provider collaboration platforms for real-time
coverage decision support (Eviti and NaviNet), molecular analysis
(GPS Cancer), and data solutions that provide multi-data analysis,
reporting and professional services offerings (Quadris). OpenNMS, a
NantHealth subsidiary, helps businesses monitor and manage network
health and performance. For more information, visit nanthealth.com,
follow us on Twitter, Facebook and LinkedIn, and subscribe to our
blog.
Forward Looking Statement
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to integrate OpenNMS into our operations;;
our ability to obtain regulatory approvals; dependence upon senior
management; the need to comply with and meet applicable laws and
regulations; unexpected adverse events; clinical adoption and
market acceptance of GPS Cancer; and anticipated cost savings. We
undertake no obligation to update any forward-looking statement in
light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210505005388/en/
Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024